Which Is Worse: Hodgkin or Non-Hodgkin Lymphoma?

Non-Hodgkin lymphoma is generally considered harder to cure than Hodgkin lymphoma, but that comparison hides enormous complexity. Hodgkin lymphoma has long been one of the most treatable cancers, with survival rates above 80 percent overall and above 90 percent in younger patients. Non-Hodgkin lymphoma, however, is not one disease but an umbrella term for more than 30 distinct cancers, some of which are more aggressive than any Hodgkin subtype and others so slow-growing they may never need treatment at all. Asking which is “worse” turns out to be the wrong question once you understand what each label actually means.

What Makes Hodgkin and Non-Hodgkin Lymphoma Different

Both diseases start in the lymphatic system, but the resemblance fades quickly at the cellular level. Classical Hodgkin lymphoma is defined by the presence of distinctive giant cells called Reed-Sternberg cells, which are surrounded by a characteristic mix of immune cells that make up most of the tumor mass.¹ In non-Hodgkin lymphoma, cells resembling Reed-Sternberg cells occasionally appear, but they behave differently and lack the surrounding immune-cell environment that typifies Hodgkin disease.² Getting this distinction right under the microscope matters because the two diseases respond to fundamentally different treatment strategies.

The diseases also tend to show up in different places in the body. Hodgkin lymphoma usually involves lymph nodes and the spleen in a relatively predictable, contiguous pattern, which is part of what makes it easier to stage and treat. Non-Hodgkin lymphoma, by contrast, more frequently involves sites outside the lymph nodes, including the gut, skin, bone marrow, and brain.³ This tendency to pop up in unexpected organs is one reason NHL can be harder to track and treat.

Who Gets Each Type and When

Hodgkin lymphoma has a distinctive bimodal age pattern, with the first peak striking people between ages 15 and 35 and a second, smaller peak appearing after age 55.⁴ That first peak is why Hodgkin lymphoma is often thought of as a young person’s cancer. Non-Hodgkin lymphoma is far more common overall and tends to appear later in life, though some aggressive subtypes like Burkitt lymphoma and lymphoblastic lymphoma cluster in children and young adults.

Several infectious agents play a role in both diseases, but in different ways. Epstein-Barr virus (EBV), the virus behind mononucleosis, has a strong link to a subset of Hodgkin lymphoma cases.⁵ Research using highly sensitive detection methods has found traces of EBV in about half of classical Hodgkin lymphoma cases classified as EBV-negative by standard testing, suggesting the virus’s involvement may be even broader than previously thought.⁶ Non-Hodgkin lymphomas involve a wider cast of microbial players. Hepatitis C, the bacterium Helicobacter pylori, and HIV all increase the risk of various NHL subtypes through different mechanisms, from chronic immune stimulation to direct immune suppression.⁵ In people living with HIV, a higher viral load increases NHL risk specifically, while low CD4 counts raise the risk of both Hodgkin and non-Hodgkin lymphoma.⁷

Survival Rates and Why They Vary So Much

Hodgkin lymphoma is one of the most curable cancers. In children and young adults, long-term survival now exceeds 90 percent with modern chemotherapy, sometimes combined with radiation.⁸ Even in adults with advanced disease, the majority are cured with standard regimens like ABVD, though roughly a fifth of patients with advanced Hodgkin lymphoma do not achieve complete remission, and close to 40 percent eventually relapse with longer follow-up.⁹ Still, the overall picture for Hodgkin lymphoma is considerably brighter than for most cancers.

Non-Hodgkin lymphoma resists any single survival statistic because its dozens of subtypes behave so differently. For aggressive NHL, a widely used prognostic tool identified four risk groups with five-year survival rates ranging from 73 percent in the lowest-risk group down to 26 percent in the highest-risk group.¹⁰ Among patients 60 or younger, the spread was 83 percent at the best end to 32 percent at the worst.¹⁰ That enormous range means some people with NHL face a better prognosis than some with HL, while others face a much grimmer one. Indolent (slow-growing) NHLs, like follicular lymphoma, often allow patients to live for many years but are notoriously difficult to cure outright. Aggressive types like diffuse large B-cell lymphoma are potentially curable with intensive treatment but carry a higher upfront risk of death.

Even within Hodgkin lymphoma, subtypes matter. The uncommon variant known as nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) has five-year and ten-year overall survival rates of about 91 percent and 83 percent, compared with about 81 percent and 74 percent for classical Hodgkin lymphoma.¹¹ However, NLPHL has a catch: late relapses occurring more than five years after treatment are significantly more common than in classical Hodgkin lymphoma.¹² So even within the “better” disease, the picture has wrinkles.

The Pediatric Success Story

The progress in treating childhood lymphoma has been dramatic. Between 1975 and 2018, one-year overall survival for pediatric lymphoma patients improved by about 19 percentage points, five-year survival by roughly 42 percentage points, and ten-year survival by about 49 percentage points.¹³ Most of that improvement came from better chemotherapy combinations, risk-adapted treatment strategies, and reduced reliance on radiation. In adolescents, Hodgkin lymphoma accounts for roughly two-thirds of lymphoma cases, with the remaining third split among several NHL subtypes including diffuse large B-cell lymphoma, Burkitt lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma.¹⁴ Each of those subtypes has its own treatment approach and its own prognosis, so even among young patients, NHL is less a single diagnosis than a menu of possibilities.

Why Age Changes the Equation

Perhaps the single biggest factor that determines how “bad” either lymphoma is for a given person is age at diagnosis. In older patients, both Hodgkin and non-Hodgkin lymphoma become significantly harder to treat, and for overlapping reasons: existing health problems limit the intensity of chemotherapy that the body can handle, organs metabolize drugs less efficiently, and the bone marrow has less reserve to recover from the toxic effects of treatment.

For aggressive B-cell non-Hodgkin lymphoma, treatment-related death rates climb steadily with age, and a clear tipping point appears after age 75, where patients become especially vulnerable to infection and blood-count complications from chemoimmunotherapy.¹⁵ The problem is that reducing drug doses to lower toxicity leads to worse cancer outcomes, creating a difficult trade-off.¹⁶ Older Hodgkin lymphoma patients face a parallel dilemma: tolerance to curative chemotherapy drops sharply, leading to excessive toxicity, treatment delays, and dose reductions that undermine the chance of cure.¹⁷ This is one area where the gap between Hodgkin and non-Hodgkin lymphoma narrows considerably. The young adult with Hodgkin lymphoma has excellent odds; the 80-year-old with the same disease faces a genuinely difficult fight.

The Hidden Cost of Cure in Hodgkin Lymphoma

Here is where the “which is worse” question gets genuinely uncomfortable. Because Hodgkin lymphoma is so often cured, people live long enough to experience the long-term damage caused by treatment, and that damage can be severe. A Dutch study tracking survivors for a median of 19 years found that over a thousand second cancers developed among the cohort, representing a risk roughly four and a half times that of the general population. That elevated risk persisted for more than 35 years after treatment, and the cumulative chance of developing a second cancer reached nearly 49 percent at the 40-year mark.¹⁸ The most commonly seen second cancers in survivors include breast cancer, thyroid cancer, and soft-tissue sarcomas, with common adult cancers like colorectal and lung cancer also appearing at younger-than-expected ages with extended follow-up.¹⁹

The heart is another major concern. Radiation aimed at the chest, which was historically a cornerstone of Hodgkin treatment, is an independent risk factor for cardiovascular disease. Research has shown it raises the odds of heart valve disease by roughly sixfold and coronary artery disease by roughly fourfold.²⁰ Lung function can also take a hit. Patients treated with both chemotherapy and chest radiation have shown measurable declines in key breathing measurements after treatment, though some of these recovered over the following year.²¹

Modern treatment strategies have been working to shrink these risks by using lower doses of radiation, smaller radiation fields, and less toxic chemotherapy combinations. But for the tens of thousands of people treated in earlier decades, these late effects are an ongoing reality. A person cured of Hodgkin lymphoma at age 25 may spend the next 40 years managing consequences of that cure, from annual cancer screenings to cardiac monitoring. The disease may be “better” in terms of initial survival, but the lived experience of survivorship can be surprisingly burdensome.

Fertility and Family Planning

Because lymphoma often strikes people in their reproductive years, the impact on fertility deserves its own attention. The risk depends heavily on which drugs are used. Alkylating agents, particularly procarbazine and cyclophosphamide, cause prolonged absence of sperm production in 90 to 100 percent of men and premature ovarian failure in 5 to 25 percent of women under 30.²² The ABVD regimen, now the standard for most Hodgkin lymphoma patients, carries a much lower fertility risk, with infertility rates below 10 percent.²² Patients who need salvage therapy with high-dose chemotherapy and stem cell transplant face the highest risk of all.²³

Current guidelines recommend that all men facing lymphoma treatment be offered sperm cryopreservation before starting chemotherapy, regardless of the specific regimen.²⁴ For women, options include embryo or egg freezing, though these require at least a few weeks’ delay before treatment can begin. The conversation about fertility should happen at diagnosis, not after treatment has started, because some of the damage is irreversible and some preservation methods need advance planning. This applies equally to both Hodgkin and non-Hodgkin lymphoma patients, though the specific risk level varies by protocol.

Life After Treatment

Surviving lymphoma does not mean returning to the health you had before. A large European study of more than 3,600 long-term survivors found that fatigue levels were similar between Hodgkin and non-Hodgkin lymphoma survivors overall, with roughly six in ten reporting health disorders. Those with health problems had significantly higher fatigue. An interesting pattern emerged with age: Hodgkin survivors showed steadily increasing fatigue as they got older, while non-Hodgkin survivors maintained a relatively constant fatigue level until about age 70, after which it rose.²⁵ This difference likely reflects the earlier average age of Hodgkin diagnosis and the cumulative burden of late treatment effects layered on top of normal aging.

The fatigue finding underscores something that survival statistics alone miss. You can be cured of your lymphoma and still feel profoundly unwell years later. Fatigue, anxiety about relapse, cardiac monitoring, fertility loss, and the psychological weight of living under heightened cancer surveillance all shape what survivorship actually feels like. For people weighing “which is worse,” these realities matter as much as whether the five-year survival rate ends in a high or low number.

When Non-Hodgkin Lymphoma Comes Back

For patients with aggressive B-cell NHL who relapse after initial treatment or never fully respond to it, the landscape has shifted in recent years with the arrival of CAR-T cell therapy, a treatment in which a patient’s own immune cells are engineered to attack the lymphoma. In one trial of relapsed or refractory B-cell NHL patients receiving CAR-T therapy, adding a maintenance immunotherapy drug afterward improved the response rate to about 83 percent compared with 60 percent without maintenance, and two-year progression-free survival roughly tripled from about 21 percent to 60 percent.²⁶ When CAR-T therapy was combined with stem cell transplant, however, the addition of maintenance immunotherapy did not provide a clear extra benefit.²⁶ These are still relatively early results, but they represent options that simply did not exist a decade ago, and they are gradually improving what was previously a grim outlook for relapsed aggressive NHL.

New Diagnostic Tools on the Horizon

One of the persistent challenges in non-Hodgkin lymphoma is that accurate subtyping usually requires a tissue biopsy, which can be invasive and sometimes hard to obtain when disease is in a difficult location. Liquid biopsy, which analyzes fragments of tumor DNA circulating in the blood, is emerging as a potential way to subtype NHL without a surgical procedure.²⁷ About 85 percent of NHLs originate from B cells and the remainder from T cells, and the more than 30 recognized subtypes each carry distinct genetic fingerprints that blood-based tests may eventually be able to distinguish. This technology is not yet standard practice, but it could be particularly valuable for older or frail patients who are poor candidates for biopsy.

Why Dogs Are Helping Researchers Understand NHL

An unexpected ally in lymphoma research is the domestic dog. Lymphoma is the most common blood cancer in dogs, and it turns out to share striking biological similarities with human non-Hodgkin lymphoma, not just in how the cells look under a microscope but in the molecular abnormalities driving the disease.²⁸ Dogs develop lymphoma spontaneously rather than through genetic engineering, they share their owners’ environment, and their disease progresses on a compressed timeline that makes clinical trials faster and cheaper. Different breeds have different predispositions, which creates naturally occurring genetic subgroups researchers can study.²⁹ Several experimental treatments have been tested in dogs first before moving to human trials, making veterinary oncology an active contributor to the search for better NHL therapies.

When Global Access Shapes Outcomes More Than Biology

Any discussion of which lymphoma is “worse” carries an uncomfortable asterisk: outcomes depend enormously on where in the world you happen to live and what resources are available to you. Despite advances in treatment, outcomes vary dramatically both between and within populations.³⁰ In high-income countries with access to PET-CT staging, modern chemotherapy, immunotherapy, and CAR-T cells, the prognosis for both Hodgkin and many non-Hodgkin lymphomas has improved steadily. In lower-resource settings, even the highly curable Hodgkin lymphoma can be deadly when patients present late, lack access to standard drugs, or cannot complete the full course of treatment. For non-Hodgkin lymphoma, the disparities are compounded by the complexity of subtyping. Without access to advanced pathology and molecular testing, patients may receive suboptimal treatment because their specific subtype was never accurately identified. In practical terms, the gap between the best and worst outcomes for either disease is driven as much by geography and economics as by tumor biology.